loader2
Login Open ICICI 3-in-1 Account

Ipca Laboratories Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Ipca Laboratories Ltd. 13 Nov 2025 14:29 PM

Q2FY26 Quarterly Result Announced for Ipca Laboratories Ltd.

Pharmaceuticals company Ipca Laboratories announced Q2FY26 results

  • Consolidated Net total Income up 9% at Rs 2,584.36 crore.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 21.68% in Q2FY26 as against @ 19.10% in Q2FY25.
  • Consolidated Net Profit at Rs 282.57 crore (after exceptional items) up 23%.
  • Exports Income up 7% at Rs 813.65 crore.
  • Indian formulations income up 8% at Rs 1018.90 crore.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q1FY26 results

  • Revenue from Operations: Rs 2,308.85 crore compared to Rs 2,092.63 crore during Q1FY25, a change of 10%.
  • EBITDA: Rs 424.58 crore compared to Rs 387.49 crore during Q1FY25, change 10%.
  • PBT: Rs 234.42 crore compared to Rs 198.98 crore during Q1FY25, change 18%.
  • PAT: Rs 233.21 crore compared to Rs 192.24 crore during Q1FY25, change 21%.
  • EPS: Rs 9.19 for Q1FY26.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Standalone Net total Income up 9% at Rs 1,659.93 crore.
  • Consolidated Net total Income up 11% at Rs 2,272.51 crore.
  • Indian formulations income up 11% at Rs 764.05 crore.
  • Exports Income up 6% at Rs 774.29 crore. • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 21.19% in Q4FY25 as against @ 18.50% in Q4FY24.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.24 % in Q4FY25 as against @ 14.98 % in Q4FY24.
  • Standalone Net Profit at Rs 216.49 crore (before exceptional items) up 36%.
  • Consolidated Net Profit at Rs 270.83 crore (before exceptional items) up 94%.
  • The Board has recommended a final dividend of Rs 2/- per share (200%).

FY25 Financial Highlights:

  • Standalone Net Total Income up 8% at Rs 6,749.21 crore.
  • Consolidated Net Total Income up 15% at Rs 9,032.39 crore.
  • Indian formulations income up 12% at Rs 3,455.10 crore.
  • Exports Income up 4% at Rs 2,808.96 crore.
  • Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 22.66% in FY25 as against @ 19.29 % in FY24.
  • Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 18.94% in FY25 as against @ 16.72% in FY24.
  • Standalone Net Profit at Rs 932.30 crore (before exceptional items) up 40%.
  • Consolidated Net Profit at Rs 992.58 crore (before exceptional items) up 56%.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q3FY25 results

  • Standalone Net total Income up 10% at Rs 1,680.09 crore.
  • Consolidated Net total Income up 9% at Rs 2,265.48 crore.
  • Indian formulations income up 13% at Rs 877.17crore.
  • Exports Income up 6% at Rs 680.91 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 24.25% in Q3FY25 as against @ 18.52% in Q3FY24.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 19.87% in Q3FY25 as against @ 16.10% in Q3FY24.
  • Standalone Net Profit at Rs 267.56 crore (after exceptional items) up 95%.
  • Consolidated Net Profit at Rs 248.14 crore (after exceptional items) up 38%.

Result PDF

Pharmaceuticals company Ipca Laboratories announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Standalone Net total Income up 8% at Rs 1827.94 crore.
  • Consolidated Net total Income up 15% at Rs 2381.16 crore.
  • Indian formulations income up 11% at Rs 940.51 crore.
  • Exports Income up 6% at Rs 762.90 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.89% in Q2FY25 as against @ 20.86% in Q2FY24.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) . @1.9.10% in Q2FY25 as against@ 17.64 % in Q2FY24.
  • Standalone Net Profit at Rs 244.12 crore (after exceptional items) up 51%.
  • Consolidated Net Profit at Rs 229.48 crore (after exceptional items) up 58%.
  • The Board has declared an interim dividend of Rs 2/- per share (200%).

H1FY25 Financial Highlights:

  • Standalone Net Total Income up 6% at Rs 3409.19 crore.
  • Consolidated Net Total Income up 21% at Rs 4494.40 crore.
  • Indian formulations income up 11 % at Rs 1813.88 crore.
  • Exports Income up 1 % at Rs 1353.76 crore.
  • Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 22.59 % in FY25 as against @ 20.04 % in FY24.
  • Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 18.83% in FY25 as against @ 18.05% in FY24.
  • Standalone Net Profit at Rs 448.25 crore (after exceptional items) up 36%.
  • Consolidated Net Profit at Rs 421.72 crore (after exceptional items) up 37%.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q1FY25 results:

  • Standalone Net total Income up 3% at Rs 1,581.25 crore. 
  • Consolidated Net total Income up 30% at Rs 2,113.24 crore. 
  • Indian formulations income up 12% at Rs 873.37 crore.
  • Exports Income down 4% at Rs 590.86 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.25% in Q1FY25 as against @19.13% in Q1FY24. 
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.52 % in Q1FY25 as against @ 18.57 % in Q1FY24.
  • Standalone Net Profit at Rs 204.13 crore (after exceptional items) up 23%.
  • Consolidated Net Profit at Rs 192.24 crore (after exceptional items) up 18 %.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Standalone Net total Income up 6% at Rs 1,525.72 crore.
  • Consolidated Net total Income up 33% at Rs 2,051.93 crore.
  • Indian formulations income up 13% at Rs 689.83 crore.
  • Exports Income up 7% at Rs 731.38 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 18.50% in Q4 FY24 as against @ 11.75% in Q4 FY23.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items).@ 14.98% in Q4 FY24 as against @11.29% in Q4 FY23.
  • Standalone Net Profit at Rs 64.76 crore (after exceptional items) down 24%.
  • Consolidated Net Profit at Rs 59.59 crore (after exceptional items) down 22%.
  • The Board has recommended final dividend of Rs 2/- per share (200%)

FY24 Financial Highlights:

  • Standalone Net Total Income up 6% at Rs 6,111 crore.
  • Consolidated Net Total Income up 23% at Rs 7,829.81 crore.
  • Indian formulations income up 12% at Rs 3,097.16 crore.
  • Exports Income up 2% at Rs 2,707.70 crore.
  • Standalone EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 19.29% in FY24 as against @ 16.22% in FY23
  • Consolidated EBITDA margin (before forex (gain) / loss, other income and exceptional items) @ 16.72% in FY24 as against @ 15.35% in FY23
  • Standalone Net Profit at Rs 530.41 crore (after exceptional items) up 5%.
  • Consolidated Net Profit at Rs 547.35 crore (after exceptional items) up 16%

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q3FY24 & 9MFY24 results:

Q3FY24 Financial Highlights:

  • Standalone Net Total Income increased by 4% to Rs 1,523.72 crore.
  • Consolidated Net Total Income surged by 32% to Rs 2,075.31 crore.
  • Indian formulations income grew by 11% to Rs 779.61 crore.
  • Exports Income rose by 1% to Rs 640.34 crore.
  • Standalone EBITDA margin (before forex gain/loss and other income) stood at 18.55% in Q3FY24, compared to 15.77% in Q3FY23.
  • Consolidated EBITDA margin (before forex gain/loss, other income, and exceptional items) stood at 16.12% in Q3FY24, compared to 15.00% in Q3FY23.
  • Standalone Net Profit increased by 19% to Rs 136.94 crore.
  • Consolidated Net Profit surged by 67% to Rs 179.88 crore.

9MFY24 Financial Highlights:

  • Standalone Net Total Income grew by 6% to Rs 4,752.03 crore.
  • Consolidated Net Total Income increased by 20% to Rs 5,777.88 crore.
  • Indian formulations income rose by 12% to Rs 2,407.33 crore.
  • Exports Income increased by 1% to Rs 1,976.32 crore.
  • Standalone EBITDA margin (before forex gain/loss, other income, and Unichem acquisition cost) stood at 19.55% in 9MFY24, compared to 17.63% in 9MFY23.
  • Consolidated EBITDA margin (before forex gain/loss, other income, Unichem acquisition cost, and exceptional items) stood at 17.34% in 9MFY24, compared to 16.64% in 9MFY23.
  • Standalone Net Profit grew by 11% to Rs 465.65 crore.
  • Consolidated Net Profit increased by 24% to Rs 487.76 crore.

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q2FY24 results:

  • Standalone Net Total Income up 11% at Rs 1,698.81 crore.
  • Consolidated Net Total Income up 27% at Rs 2,072.51 crore.
  • Indian formulations income is up 10 % at Rs 844.99 crore.
  • Exports Income is up 14 % at Rs 720.72 crore.
  • Standalone EBITDA margin (before forex (gain)/loss, other income, and Unichem acquisition cost) at 20.86% in Q2FY24 as against 18.85% in Q2FY23.
  • Consolidated EBITDA margin (before forex (gain)/loss, other income, and Unichem acquisition cost) at 17.64% in Q2FY24 as against 17% in Q2FY23.
  • Standalone Net Profit at Rs 162.13 crore down 2%.
  • Consolidated Net Profit at Rs 145.06 crore up 1%.
  • The Board has declared an interim dividend of Rs 21- per share (200%).

 

 

 

Result PDF

Pharmaceuticals company Ipca Laboratories announced Q1FY24 results:

  • Consolidated Q1FY24:
    • Net Total Income of Rs 1,632.43 crore in Q1FY24 as against Rs 1,607.85 crore in Q1FY23.
    • EBIDTA margin (before forex (gain)/loss and other income) of 18.53% in Q1FY24 as against 17.88% in Q1FY23.
    • Net Profit up 14% at Rs 162.82 crore.
  • Standalone Q1FY24:
    • Net Total Income of Rs 1,531.87 crore in Q1FY24 as against Rs 1,496.24 crore in Q1FY23.
    • Exports Income of Rs 615.26 crore in Q1FY24 as against Rs 689.41 crore in Q1FY23.
    • EBIDTA margin (before forex (gain)/loss and other income) of 19.08% in Q1FY24 as against 18.21% in Q1FY23.
    • Net Profit up 19% at Rs 166.58 crore.

 

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app